Published in Cancer Res on August 15, 2004
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell (2009) 8.21
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 6.61
Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 6.31
Tumor-associated macrophages: from mechanisms to therapy. Immunity (2014) 4.69
Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev (2008) 4.40
Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis (2010) 4.24
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med (2006) 4.20
Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res (2009) 4.16
Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog (2009) 4.12
Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol (2010) 3.86
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med (2005) 3.80
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med (2006) 3.75
Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res (2008) 3.57
Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol (2005) 3.20
L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood (2006) 3.17
History of myeloid-derived suppressor cells. Nat Rev Cancer (2013) 3.14
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med (2005) 3.13
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother (2011) 2.97
Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother (2005) 2.87
Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood (2007) 2.65
Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol (2009) 2.59
Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A (2005) 2.49
Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res (2010) 2.48
Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res (2009) 2.02
Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol (2012) 2.01
Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res (2009) 1.99
Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer (2013) 1.96
Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol (2010) 1.94
Commensal bacteria at the interface of host metabolism and the immune system. Nat Immunol (2013) 1.93
Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells. Stem Cells (2010) 1.75
Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med (2008) 1.70
The metabolic life and times of a T-cell. Immunol Rev (2010) 1.57
Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother (2012) 1.55
Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. PLoS One (2011) 1.50
Crystal structure of human arginase I at 1.29-A resolution and exploration of inhibition in the immune response. Proc Natl Acad Sci U S A (2005) 1.46
Host A(2B) adenosine receptors promote carcinoma growth. Neoplasia (2008) 1.43
Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest (2012) 1.43
Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties. Eur J Immunol (2010) 1.39
Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res (2012) 1.37
Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res (2005) 1.36
Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res (2008) 1.32
Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study. BMC Cancer (2010) 1.31
Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol (2012) 1.30
Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells. Cancer Immunol Immunother (2008) 1.30
Multifactorial etiology of gastric cancer. Methods Mol Biol (2012) 1.29
Myeloid suppressor cells regulate the adaptive immune response to cancer. J Clin Invest (2006) 1.29
Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis. Blood (2007) 1.29
Local suppression of T cell responses by arginase-induced L-arginine depletion in nonhealing leishmaniasis. PLoS Negl Trop Dis (2009) 1.29
Targeting T cell metabolism for therapy. Trends Immunol (2015) 1.27
Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Mol Immunol (2008) 1.27
Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase. J Immunol (2011) 1.26
Regulatory dendritic cells: there is more than just immune activation. Front Immunol (2012) 1.25
Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Adv Cancer Res (2015) 1.25
Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Curr Cancer Drug Targets (2011) 1.22
L-arginine metabolism and its impact on host immunity against Leishmania infection. Immunol Res (2008) 1.21
Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction. Oncoimmunology (2012) 1.19
Tumor-altered dendritic cell function: implications for anti-tumor immunity. Front Immunol (2013) 1.17
Pegylated arginase I: a potential therapeutic approach in T-ALL. Blood (2010) 1.17
Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunol Rev (2012) 1.16
Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov (2015) 1.12
Gr1(int)CD11b+ myeloid-derived suppressor cells in Mycobacterium tuberculosis infection. PLoS One (2013) 1.10
L-arginine deprivation regulates cyclin D3 mRNA stability in human T cells by controlling HuR expression. J Immunol (2010) 1.06
Tryptophan hydroxylase-1 regulates immune tolerance and inflammation. J Exp Med (2012) 1.06
Increased level of arginase activity correlates with disease severity in HIV-seropositive patients. J Infect Dis (2010) 1.05
Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways. Int J Cancer (2013) 1.04
The role of leishmania proteophosphoglycans in sand fly transmission and infection of the Mammalian host. Front Microbiol (2012) 1.03
Arginase blockade protects against hepatic damage in warm ischemia-reperfusion. Nitric Oxide (2008) 1.03
Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology (2015) 1.03
Immune evasion by Helicobacter pylori is mediated by induction of macrophage arginase II. J Immunol (2011) 1.02
Combinations of immunotherapy and radiation in cancer therapy. Front Oncol (2014) 1.01
Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-β-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells. J Leukoc Biol (2012) 1.00
Complex role for the immune system in initiation and progression of pancreatic cancer. World J Gastroenterol (2014) 1.00
Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship. Immunol Invest (2012) 1.00
Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death Dis (2012) 1.00
Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res (2013) 0.99
L-arginine deprivation impairs Leishmania major-specific T-cell responses. Eur J Immunol (2009) 0.99
Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies. Cancer Immunol Res (2015) 0.98
Progressive visceral leishmaniasis is driven by dominant parasite-induced STAT6 activation and STAT6-dependent host arginase 1 expression. PLoS Pathog (2012) 0.97
Orchestration of angiogenesis by immune cells. Front Oncol (2014) 0.97
Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression. Cancer Discov (2016) 0.97
Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis. PLoS One (2011) 0.96
Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry B Clin Cytom (2014) 0.95
Retinoic acid promotes the development of Arg1-expressing dendritic cells for the regulation of T-cell differentiation. Eur J Immunol (2013) 0.95
Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front Oncol (2013) 0.95
Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells. Semin Cancer Biol (2012) 0.95
Myeloid derived suppressor cells: Targets for therapy. Oncoimmunology (2013) 0.94
Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. Front Oncol (2014) 0.94
Expression of NF-κB p50 in tumor stroma limits the control of tumors by radiation therapy. PLoS One (2012) 0.94
Requirement for inducible nitric oxide synthase in chronic allergen exposure-induced pulmonary fibrosis but not inflammation. J Immunol (2010) 0.93
Arginine depletion as a mechanism for the immune privilege of corneal allografts. Eur J Immunol (2011) 0.93
l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells. Cancer Res (2014) 0.93
The impact of the myeloid response to radiation therapy. Clin Dev Immunol (2013) 0.92
Differential impact of L-arginine deprivation on the activation and effector functions of T cells and macrophages. J Leukoc Biol (2008) 0.92
Neoplastic "Black Ops": cancer's subversive tactics in overcoming host defenses. Semin Cancer Biol (2012) 0.92
Modulating the expression of IFN regulatory factor 8 alters the protumorigenic behavior of CD11b+Gr-1+ myeloid cells. J Immunol (2009) 0.92
Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunol Immunother (2014) 0.92
Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy. NPJ Breast Cancer (2016) 0.92
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res (2005) 6.66
Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr (2009) 6.54
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet (2011) 5.21
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10
Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev (2008) 4.40
Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res (2009) 4.16
All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res (2006) 4.06
HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med (2010) 4.00
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest (2010) 3.97
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med (2005) 3.80
Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res (2007) 3.66
Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol (2011) 3.40
L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood (2006) 3.17
CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol (2006) 3.15
Functional adaptation of BabA, the H. pylori ABO blood group antigen binding adhesin. Science (2004) 3.06
L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol (2003) 2.91
Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA (2010) 2.78
Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem (2002) 2.62
Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol (2009) 2.53
Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition: Executive Summary. Crit Care Med (2009) 2.53
A critical role for Stat3 signaling in immune tolerance. Immunity (2003) 2.41
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol (2008) 2.35
Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med (2010) 2.21
Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res (2010) 2.19
An FFP:PRBC transfusion ratio >/=1:1.5 is associated with a lower risk of mortality after massive transfusion. J Trauma (2008) 2.15
Helicobacter pylori genome evolution during human infection. Proc Natl Acad Sci U S A (2011) 2.15
Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res (2011) 2.10
Regulation of gastric carcinogenesis by Helicobacter pylori virulence factors. Cancer Res (2008) 2.08
Phylogeographic origin of Helicobacter pylori is a determinant of gastric cancer risk. Gut (2011) 2.08
Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res (2009) 1.99
The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol (2008) 1.98
Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol (2007) 1.91
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 1.88
Perioperative use of arginine-supplemented diets: a systematic review of the evidence. J Am Coll Surg (2011) 1.82
Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol (2013) 1.81
Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2006) 1.69
Arginine and immunity. J Nutr (2007) 1.62
Virulence-associated genotypes of Helicobacter pylori: do they explain the African enigma? Am J Gastroenterol (2002) 1.60
Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res (2003) 1.56
Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol (2013) 1.55
Decreased expression of CD3zeta and nuclear transcription factor kappa B in patients with pulmonary tuberculosis: potential mechanisms and reversibility with treatment. J Infect Dis (2006) 1.53
Delayed rise in incidence of gastric cancer in females results in unique sex ratio (M/F) pattern: etiologic hypothesis. Gastric Cancer (2002) 1.48
Human and Helicobacter pylori coevolution shapes the risk of gastric disease. Proc Natl Acad Sci U S A (2014) 1.48
A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma (2011) 1.47
Crystal structure of human arginase I at 1.29-A resolution and exploration of inhibition in the immune response. Proc Natl Acad Sci U S A (2005) 1.46
Effect of calorically dense enteral nutrition formulas on outcome in critically ill trauma and surgical patients. JPEN J Parenter Enteral Nutr (2007) 1.46
L-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes. Cell Immunol (2005) 1.45
Iron deficiency accelerates Helicobacter pylori-induced carcinogenesis in rodents and humans. J Clin Invest (2012) 1.45
Regulation of p53 tumor suppressor by Helicobacter pylori in gastric epithelial cells. Gastroenterology (2010) 1.45
Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother (2013) 1.43
Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest (2012) 1.43
Intestinal helminthiasis in Colombian children promotes a Th2 response to Helicobacter pylori: possible implications for gastric carcinogenesis. Cancer Epidemiol Biomarkers Prev (2005) 1.43
Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses. J Immunol (2004) 1.42
Spermine oxidase mediates the gastric cancer risk associated with Helicobacter pylori CagA. Gastroenterology (2011) 1.41
Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2011) 1.41
Helicobacter pylori arginase inhibits T cell proliferation and reduces the expression of the TCR zeta-chain (CD3zeta). J Immunol (2004) 1.37
Indoleamine 2,3-dioxygenase: is it an immune suppressor? Cancer J (2010) 1.36
Soft tissue sarcoma. J Natl Compr Canc Netw (2010) 1.34
Analysis of factorial time-course microarrays with application to a clinical study of burn injury. Proc Natl Acad Sci U S A (2010) 1.33
Interaction of Helicobacter pylori with gastric epithelial cells is mediated by the p53 protein family. Gastroenterology (2008) 1.33
Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer (2008) 1.32
Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood (2004) 1.30
Eosinophils and mast cells in chronic gastritis: possible implications in carcinogenesis. Hum Pathol (2008) 1.27
Race, African ancestry, and Helicobacter pylori infection in a low-income United States population. Cancer Epidemiol Biomarkers Prev (2011) 1.26
Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol (2008) 1.26
The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. Am J Surg (2007) 1.21
Incidence of esophageal and gastric cancers among Hispanics, non-Hispanic whites and non-Hispanic blacks in the United States: subsite and histology differences. Cancer Causes Control (2007) 1.20
Genomic changes during chronic Helicobacter pylori infection. J Bacteriol (2006) 1.20
Age at acquisition of Helicobacter pylori infection: comparison of two areas with contrasting risk of gastric cancer. Helicobacter (2004) 1.18
Promoter DNA hypermethylation in gastric biopsies from subjects at high and low risk for gastric cancer. Int J Cancer (2010) 1.18